- Cybin Inc. (CYBN, Financial) secures a U.S. patent for its CYB003 program, offering exclusivity until 2041.
- CYB003 is currently in Phase 3 trials for the treatment of Major Depressive Disorder (MDD).
- The company plans to initiate a second Phase 3 study, EMBRACE, by mid-2025.
Cybin Inc. (CYBN), a clinical-stage neuropsychiatry company, has announced the acquisition of a new U.S. patent supporting its CYB003 program. This patent grants pharmaceutical compositions and oral dosage forms within the CYB003 program with exclusivity expected until 2041. This development plays a crucial role in Cybin's efforts to revolutionize mental health treatment, particularly for Major Depressive Disorder (MDD).
The CYB003 program is a proprietary deuterated psilocin analog currently in the pivotal Phase 3 study, APPROACH, focusing on providing an adjunctive treatment for MDD. Cybin is committed to creating innovative treatments addressing the significant unmet needs in the mental health sector and aims to commence its second Phase 3 study, EMBRACE, by mid-2025.
Doug Drysdale, CEO of Cybin, highlighted the importance of securing robust patent protection as a foundation for drug development and commercialization, ensuring shareholder value and advancing effective treatments for mental health disorders. This newly issued patent adds to Cybin's expanding intellectual property portfolio, which already includes over 80 granted patents and more than 230 pending applications.
